Titel och upphov Rare disease drug development : clinical, scientific, patient, and caregiver perspectives
Antal i kö: NU (US)
Utgivning, distribution, etc. Springer, Cham, Switzerland : 2021.
DDC klassifikationskod (Dewey Decimal Classification)
Fysisk beskrivning
Anmärkning: Allmän
Anmärkning: Innehåll Introduction to Rare Diseases and Market Overview -- The Patient Perspective -- Select Patient Narratives -- The Caregiver Perspective -- The Critical, Multidimensional Role of Patient Advocacy Groups in Rare Disease -- A Mental Health Perspective -- Investment Decisions Related to Rare Disease Drug Development -- Optimizing Rare Disease Registries and Natural History Studies -- Novel Approaches to Clinical Trials in Rare Diseases -- Patient Benefits from Innovative Designs in Rare Diseases -- Central Nervous System Rare Disease Drug Development -- Oncologic Rare Disease Drug Development -- Hematologic Rare Disease Drug Development -- Lessons From Rare Disease and Gene Therapy Clinical Studies in Ophthalmology -- Rare Diseases in the Pediatric Population -- Cell and Gene Therapy in Rare Diseases -- The Feasibility Assessment -- The Evolving Regulatory Space and the Advent of Patient-Focused Drug Development -- Operational Aspects of Rare Disease Drug Development -- Accelerating Rare Disease Drug Development -- Select Rare Disease Drug Approvals: Lessons Learned -- A Rapid Market Access Strategy for Orphan Medicinal Products (OMPs) with Highlights Regarding the Pricing and Reimbursement Process and Barriers to Patient Use -- Integrated Life Cycle Management for Rare and Orphan Products -- The Case for Real-World Data and Real-World Evidence Generation in Rare and Orphan Medicinal Drug Development -- Closing Remarks --
Anmärkning: Innehållsbeskrivning, sammanfattning This book provides a broad overview of rare disease drug development. It offers unique insights from various perspectives, including third-party capital providers, caregivers, patient advocacy groups, drug development professionals, marketing and commercial experts, and patients. A unique reference, the book begins with narratives on the many challenges faced by rare disease patient and their caregivers. Subsequent chapters underscore the critical, multidimensional role of patient advocacy groups and the novel approaches to related clinical trials, investment decisions, and the optimization of rare disease registries. The book addresses various rare disease drug development processes by disciplines such as oncology, hematology, pediatrics, and gene therapy. Chapters then address the operational aspects of drug development, including approval processes, development accelerations, and market access strategies. The book concludes with reflections on the authors' case for real-world data and evidence generation in orphan medicinal drug development. Rare Disease Drug Development is an expertly written text optimized for biopharmaceutical R & D experts, commercial experts, third-party capital providers, patient advocacy groups, patients, and caregivers.
Ämnesordsbiuppslag - Term
Indexterm - Genre/Form Electronic books. Electronic books.
Biuppslag - Personnamn
Länkfält - Annat medium Print version: Rare disease drug development. Cham, Switzerland : Springer, 2021 ISBN 3030786048 ISBN 9783030786045
ISBN
*00000000cam a2200000 a 4500
*00175203
*00520220527105014.0
*006m o d
*007cr |n|||||||||
*008211115s2021 sz o 001 0 eng d
*019 $a1285162888$a1285167076$a1285238723$a1285253297$a1285781995$a1292517551$a1294357270
*020 $a9783030786052$q(electronic bk.)
*020 $a3030786056$q(electronic bk.)
*020 $z3030786048
*020 $z9783030786045
*0247 $a10.1007/978-3-030-78605-2$2doi
*029 $aAU@$b000070289596
*035 $a(OCoLC)1285274795$z(OCoLC)1285162888$z(OCoLC)1285167076$z(OCoLC)1285238723$z(OCoLC)1285253297$z(OCoLC)1285781995$z(OCoLC)1292517551$z(OCoLC)1294357270
*035 $a(OCoLC)on1285274795
*037 $bSpringer
*040 $aYDX$beng$epn$cYDX$dGW5XE$dEBLCP$dOCLCF$dDKU$dOCLCO$dDCT$dOCLCQ$dCOM$dOCLCO
*049 $aMAIN
*050 4$aRM301.25
*072 7$aMED000000$2bisacsh
*072 7$aMB$2bicssc
*072 7$aMB$2thema
*08204$a615.1/9$223
*24500$aRare disease drug development :$bclinical, scientific, patient, and caregiver perspectives /$cRaymond A. Huml, editor.
*260 $aCham, Switzerland :$bSpringer,$c2021.
*300 $a1 online resource
*336 $atext$btxt$2rdacontent
*337 $acomputer$bc$2rdamedia
*338 $aonline resource$bcr$2rdacarrier
*347 $atext file
*347 $bPDF
*500 $aIncludes index.
*5050 $aIntroduction to Rare Diseases and Market Overview -- The Patient Perspective -- Select Patient Narratives -- The Caregiver Perspective -- The Critical, Multidimensional Role of Patient Advocacy Groups in Rare Disease -- A Mental Health Perspective -- Investment Decisions Related to Rare Disease Drug Development -- Optimizing Rare Disease Registries and Natural History Studies -- Novel Approaches to Clinical Trials in Rare Diseases -- Patient Benefits from Innovative Designs in Rare Diseases -- Central Nervous System Rare Disease Drug Development -- Oncologic Rare Disease Drug Development -- Hematologic Rare Disease Drug Development -- Lessons From Rare Disease and Gene Therapy Clinical Studies in Ophthalmology -- Rare Diseases in the Pediatric Population -- Cell and Gene Therapy in Rare Diseases -- The Feasibility Assessment -- The Evolving Regulatory Space and the Advent of Patient-Focused Drug Development -- Operational Aspects of Rare Disease Drug Development -- Accelerating Rare Disease Drug Development -- Select Rare Disease Drug Approvals: Lessons Learned -- A Rapid Market Access Strategy for Orphan Medicinal Products (OMPs) with Highlights Regarding the Pricing and Reimbursement Process and Barriers to Patient Use -- Integrated Life Cycle Management for Rare and Orphan Products -- The Case for Real-World Data and Real-World Evidence Generation in Rare and Orphan Medicinal Drug Development -- Closing Remarks --
*520 $aThis book provides a broad overview of rare disease drug development. It offers unique insights from various perspectives, including third-party capital providers, caregivers, patient advocacy groups, drug development professionals, marketing and commercial experts, and patients. A unique reference, the book begins with narratives on the many challenges faced by rare disease patient and their caregivers. Subsequent chapters underscore the critical, multidimensional role of patient advocacy groups and the novel approaches to related clinical trials, investment decisions, and the optimization of rare disease registries. The book addresses various rare disease drug development processes by disciplines such as oncology, hematology, pediatrics, and gene therapy. Chapters then address the operational aspects of drug development, including approval processes, development accelerations, and market access strategies. The book concludes with reflections on the authors' case for real-world data and evidence generation in orphan medicinal drug development. Rare Disease Drug Development is an expertly written text optimized for biopharmaceutical R & D experts, commercial experts, third-party capital providers, patient advocacy groups, patients, and caregivers.
*5880 $aOnline resource; title from PDF title page (SpringerLink, viewed November 23, 2021).
*650 0$aDrug development.
*650 0$aRare diseases $xChemotherapy.
*650 6$aMédicaments$xDéveloppement.
*650 6$aMaladies rare s$xChimiothérapie.
*650 7$aDrug development.$2fast$0(OCoLC)fst00898670
*655 0$aElectronic books.
*655 4$aElectronic books.
*7001 $aHuml, Raymond A.,$eeditor.
*77608$iPrint version:$tRare disease drug development.$dCham, Switzerland : Springer, 2021$z3030786048$z9783030786045$wIMP(OCoLC)(OCoLC)1250512598
*85640$uhttp://proxybibl.vgregion.se/login?url=https://link.springer.com/10.1007/978-3-030-78605-2$zTillgänglig via e-biblioteket Västra Götalandsregionen
*994 $a92$bSENUS
^
Det finns inga omdömen till denna titeln.
Klicka här
för att vara den första som skriver ett omdöme.